Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer

Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer

Background Ovarian cancer is the most lethal gynecological malignancy, with limited treatment options after failure of standard therapies. Despite the potential of poly(ADP-ribose) polymerase inhibitors in treating DNA damage response (DDR)-deficient ovarian cancer, the development of resistance and...

Full description

Bibliographic Details
Main Authors: Lorna Rodriguez-Rodriguez, Rui Huang, Mihaela Cristea, Qianqian Zhao, Adrian Kohut, Hua Yu, Mihae Song, Antons Martincuks, Chunyan Zhang, Edward W Wang, Theresa Austria, Yi-Jia Li, Nicole Lugo Santiago, Rosemarie Martinez Borrero, Binghui Shen
Format: Article
Language:English
Published: BMJ Publishing Group 2024-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/4/e007716.full

Internet

https://jitc.bmj.com/content/12/4/e007716.full

Similar Items